Patents Examined by Yong S. Chong
  • Tetrahydroisoquinolin-1-one derivative or salt thereof
    Patent number: 10016410
    Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 10, 2018
    Assignee: Seldar Pharma Inc.
    Inventors: Hiroyuki Hisamichi, Itsuro Shimada, Tsukasa Ishihara, Tomofumi Takuwa, Takafumi Shimizu, Noriko Ishikawa, Kyoichi Maeno, Norio Seki
  • Anti-cancer agents and preparation thereof
    Patent number: 10000505
    Abstract: Embodiments of the present invention provide, among other compounds, a family of spliceosome-inhibiting compounds that can be used as therapeutic anti-cancer agents. The compounds are synthesized in a process that includes the catalytic cross metathesis of a cyclic epoxy alcohol to an amide.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: June 19, 2018
    Assignee: Purdue Research Foundation
    Inventor: Arun K. Ghosh
  • Method for the treatment or prevention of lower urinary tract symptoms
    Patent number: 9993442
    Abstract: This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 12, 2018
    Assignee: HORMOS MEDICAL LTD.
    Inventors: Risto Santti, Tomi Streng
  • Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
    Patent number: 9968710
    Abstract: Use of a pharmaceutical composition for the local treatment or prevention of a tissue infection at an infection site, the pharmaceutical composition comprising at least two different antibiotics of group A or pharmaceutically acceptable derivatives thereof, or an antibiotic of group A and at least one antibiotic of group B or pharmaceutically acceptable derivatives thereof. Group A comprises primarily intracellular active antibiotics working as inhibitor of bacterial RNA polymerase; as inhibitor of gyrase; or as inhibitor of bacterial protein synthesis. Group B comprises primarily extracellular active antibiotics working as inhibitor of bacterial cell wall synthesis; or inhibitor of bacterial protein synthesis; or by direct destabilization or rupture of the bacterial cell wall.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: May 15, 2018
    Assignee: Biomet Deutschland GmbH
    Inventor: Nicole Duewelhenke
  • Method for use of homopiperazinium compounds in the treatment of cancer
    Patent number: 9949984
    Abstract: A method for treating cancer comprising administering to a patient in need thereof an effective amount of a compound having the formula: wherein R1 and R2 are independently alkyl of 1 to 6 carbon atoms or cycloalkyl of 3 to 6 carbon atoms, Xa is CH or N, Ya is hydrogen or a substituent, each of which is independently selected; n is an integer from 1 to 5, J is a counter ion.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: April 24, 2018
    Assignee: UNIVERSITÉ LAVAL
    Inventors: Yvon Cormier, Evelyne Israel-Assayag
  • Optimizing mifepristone levels for cushing's patients
    Patent number: 9943526
    Abstract: The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: April 17, 2018
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph Belanoff, Coleman Gross
  • Combination therapy to treat mycobacterium diseases
    Patent number: 9937192
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: April 10, 2018
    Assignee: SPERO TRINEM, INC.
    Inventors: Christopher Phillip Locher, Youssef Laafiret Bennani, Anne-Laure Grillot, Hardwin O'Dowd, Emanuele Perola, Arnaud Le Tiran, Paul S. Charifson
  • Compounds and methods for treating an epileptic disorder
    Patent number: 9925172
    Abstract: Provided, inter alia, are methods for treating an epilepsy disorder using clemizole, a clemizole analog, or pharmaceutical salts thereof.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: March 27, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Scott C. Baraban
  • Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
    Patent number: 9918948
    Abstract: The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: March 20, 2018
    Assignee: TONIX PHARMA HOLDINGS LIMITED
    Inventors: Seth Lederman, Herbert Harris
  • Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
    Patent number: 9920033
    Abstract: The present invention relates to a crystalline form of N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide p-toluenesulfonate, the process for preparing the crystalline form thereof, and the pharmaceutical compositions comprising the crystalline form thereof. This invention also relates to a method of using such a crystalline form and pharmaceutical compositions comprising the crystalline form thereof in the treatment of hyperproliferative diseases in mammals, especially in humans.
    Type: Grant
    Filed: November 12, 2016
    Date of Patent: March 20, 2018
    Assignees: Calitor Sciences, LLC, Sunshine Lake Pharma Co., LTD.
    Inventors: Ning Xi, Mingming Sun
  • Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
    Patent number: 9913829
    Abstract: The present invention relates to the compound of formula (I) for use in the treatment of a nonsense-mutation-mediated genetic disease.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITE DE DROIT ET DE SANTE DE LILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR DE LILLE
    Inventors: Fabrice Lejeune, Benoit Deprez, Terence Beghyn, Sara Sofia Gonzalez-Hilarion
  • FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
    Patent number: 8288423
    Abstract: The present invention relates to novel oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: October 16, 2012
    Assignee: Legochem Bioscience Ltd.
    Inventors: Young Lag Cho, Ho Young Song, Dae Yon Lee, Sung Yoon Baek, Sang Eun Chae, Sang Hui Jo, Yeon Ok Kim, Hyang Sook Lee, Ju Hyun Park, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
  • Optically active muscone composition and fragrances or cosmetics containing the same
    Patent number: 8227401
    Abstract: (Problem) The object of the invention relates to a development of a new musk-feeling fragrance material which is a highly scenting musk-feeling fragrance, and is to provide a fragrance composition which, when added to fragrances or cosmetics, can improve the fixative property and express a high performance and excellent musky aromatic quality. (Means for resolution) A fragrance composition is prepared using, as the active ingredient, a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 90:10 to 95:5 (weight ratio) in terms of weight ratio, or a mixture of (R)-form of optically active muscone with (S)-form of optically active muscone with the mixing ratio thereof within the range of from 75:25 to 80:20 (weight ratio) in terms of weight ratio.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: July 24, 2012
    Assignee: Takasago International Corporation
    Inventors: Kenichi Yamamoto, Misao Yagi, Hiroyuki Matsuda, Kenji Maruyama
  • Approach to anti-microbial host defense with molecular shields with lipoxin compounds
    Patent number: 7994219
    Abstract: Methods to cause tissue, such as mucosal cells, to express increased amounts of bactericidal permeability increasing protein (BPI) are described. The BPI inducing agents include, for example, lipoxin compounds.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: August 9, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Sean P. Colgan
  • Methods for treating parkinsons disease and parkinsonism
    Patent number: 7964617
    Abstract: Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome in neural cells, with or without concomitantly increasing enzyme activity in neural cells. Restoration of trafficking relieves cell stress and other toxicities associated with accumulation of mutant proteins. Restoration of enzyme activity relieves substrate accumulation and pathologies associated with lipid accumulation. In a specific embodiment, the neurological disorder is Parkinson's disease or parkinsonism which is associated with mutations in glucocerebrosidase.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: June 21, 2011
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Brandon Wustman
  • Treatment of chemokine mediated diseases
    Patent number: 7960433
    Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: June 14, 2011
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay S. Fine, Loretta A. Bober, Jianhua Chao, Purakkattle J. Biju, Younong Yu
  • Antihepatitis C virus agent and anti-HIV agent
    Patent number: 7956079
    Abstract: An anti-hepatitis C virus agent or anti-HIV agent comprising, as an active ingredient, a fullerene derivative which has a nitrogen atom forming a ring together with adjacent bonded carbon atom pairs constituting the carbon cluster skeleton of the fullerene or a quaternary amine salt thereof is provided.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: June 7, 2011
    Assignees: Mitsubishi Corporation
    Inventors: Tadahiko Mashino, Kumiko Shimotohno
  • Augmented cognitive training
    Patent number: 7947731
    Abstract: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: May 24, 2011
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Timothy P. Tully, Filippo Cavalieri
  • Microbicidal composition based on formaldehyde donor compounds and antioxidants
    Patent number: 7935701
    Abstract: Microbicidal composition for product preservation, including a microbicidal composition which comprises a) at least one formaldehyde donor compound and b) at least one antioxidant chosen from gallic esters, phenol derivatives, L-ascorbic acid, and salts and derivatives thereof, and tocopherols and derivatives thereof, and to the use thereof for the preservation of technical products, for example fuels and lubricants.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: May 3, 2011
    Assignee: Air Liquide Sante (International)
    Inventors: Ralf Gradtke, Wolfgang Beilfuss, Klaus Weber, Wolfgang Siegert
  • Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
    Patent number: 7928119
    Abstract: Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.
    Type: Grant
    Filed: November 3, 2006
    Date of Patent: April 19, 2011
    Assignee: Pfizer Inc.
    Inventors: Masato Shimojo, Kana Taniguchi